In-hospital Initiation of PCSK9 Inhibitor and Short-term Lipid Profile Alteration, as Well as In-hospital Mortality and Readmission Rate in Patients With Acute Myocardial Infarction
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 7,556
- 主要终点
- Readmission rate
研究概览
简要总结
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitor among patients with acute myocardial infarction(AMI) based on real-world experience.
A total of 7556 AMI patients from the biobank database between January 2016 and December 2020 were screened for eligibility. After excluding those without revascularization or Statin based therapy, the remaining 5802 Statin users, 801 Statin plus Ezetimibe users and 170 Statin plus Evolocumab users (including 95 users without and 75 users with Ezetimibe), were selected for this study. Then, 1st and 3rd-month follow-up data were collected and analysed, including in-hospital mortality, readmission rate and lipid profiles
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •confirmed admission diagnosis of AMI and were defined based on the universal definition criteria by the American Cardiology College
排除标准
- •(1) severe noncardiac disease with an expected survival of less than 1 year and unwillingness to participate; (2) patients over the age of 80 years or living far away from the hospital's catchment area.
研究组 & 干预措施
PCSK9i Group
AMI patients with Statin plus PCSK9i therapy.
干预措施: Evolocumab 140 MG/ML (Drug)
Triple Group
AMI patients with Statin plus Ezetimibe plus PCSK9i therapy
干预措施: Evolocumab 140 MG/ML (Drug)
结局指标
主要结局
Readmission rate
时间窗: 1 YEAR
次要结局
未报告次要终点
研究者
She JianQing
First Affiliated Hospital Xi'an Jiaotong University
First Affiliated Hospital Xi'an Jiaotong University